Patupilone (epothilone B, EPO906) inhibits growth and metastasis of experimental prostate tumors in vivo
| Autor: | Paul M.J. McSheehy, Terence O'reilly, Markus Wartmann, Juliane Vaxelaire, Melanie Müller, Marc Hattenberger, Fritz Wenger, Karl-Heinz Altmann |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
Male
medicine.medical_specialty Paclitaxel Urology Mice Nude Antineoplastic Agents Metastasis chemistry.chemical_compound Prostate cancer Mice In vivo Internal medicine Patupilone Cell Line Tumor medicine Animals Humans Mice Inbred BALB C business.industry Body Weight Cancer Prostatic Neoplasms medicine.disease Primary tumor Xenograft Model Antitumor Assays Endocrinology Oncology chemistry Epothilones Lymphatic Metastasis Cancer research Growth inhibition business |
| Zdroj: | The Prostate. 65(3) |
| ISSN: | 0270-4137 |
| Popis: | BACKGROUND Microtubule agents appear promising for the treatment of prostate cancer. Patupilone (epothilone B), a highly potent non-taxane microtubule stabilizing agent, was evaluated in models of androgen-independent prostate cancer. METHODS Patupilone was administered to athymic mice bearing human prostate cancer xenografts (subcutaneous DU 145 and PC-3M, orthotopic PC-3M). RESULTS One 4 mg/kg patupilone administration produced transient regression of DU 145 tumors, while two weekly administrations of 2.5 mg/kg produced stable disease followed by protracted regression, however with more pronounced body weight loss. Taxol® (15 mg/kg every other day) weakly inhibited tumor growth, but with less body weight loss. Patupilone (5 mg/kg) produced protracted growth inhibition of subcutaneous PC-3M tumors, with transient body weight loss. In mice with orthotopic PC-3M tumors, 4 or 5 mg/kg/week patupilone impaired primary tumor growth, abrogated metastases and enhanced survival, with only transient body weight loss. CONCLUSIONS These data suggest that patupilone holds promise for prostate cancer treatment. © 2005 Wiley-Liss, Inc. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text